Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (1013)	5/3/1999 5:51:00 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 1972

Vical Announces First-Quarter 1999 Financial Results. biz.yahoo.com

To: Scott H. Davis who wrote (1013)	5/5/1999 7:50:00 PM
From: smh	Read Replies (2) \| Respond to of 1972

Financial Times article on the prostate trials. ft.com

To: Scott H. Davis who wrote (1013)	5/5/1999 10:41:00 PM
From: A.J. Mullen	Read Replies (1) \| Respond to of 1972

Can anyone help me by explaining why they went ahead with surgery after the experimental treatment had reduced PSA level;s to "pre-surgical levels?" IS there another diagnostic? I'm woefully ignorant on this and suppose I should learn for health as well as wealth." This come from the press-relaese you posted Scott: "In eight of the 12 patients scheduled for surgery, pre-surgical serum PSA levels decreased significantly after treatment with Leuvectin. Three patients were diagnosed with metastatic disease at the time of the surgery and therefore excluded from the trial. All nine patients who remained in the trial after surgery maintained negligible PSA levels after 11 to 18 months and continuing. "